SCHEMBL3411765

SCHEMBL3411765

O=C(Nc1ccoc1)c1c(=O)[nH]n2c(=O)c3c([nH]c12)CCCC3

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.43
TDP1 Q9NUW8 4/20 0.43
L3MBTL1 Q9Y468 4/20 0.43
MEN1 O00255 9/20 0.43
KMT2A Q03164 9/20 0.43
KDM4E B2RXH2 7/20 0.43
LMNA P02545 4/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HPGD P15428 6/20 0.42
POLB P06746 5/20 0.42
HTT P42858 4/20 0.42
CRHBP P24387 2/20 0.42
CRHR2 Q13324 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
BLM P54132 2/20 0.42
CTDSP1 Q9GZU7 2/20 0.42
GAA P10253 2/20 0.42
ALPL P05186 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3410031 0.85 MAPT (0.52) MAPTTDP1L3MBTL1MEN1KMT2A
SCHEMBL3411680 0.83 MAPT (0.47) MAPTTDP1L3MBTL1MEN1KMT2A
SCHEMBL3411768 0.81 MAPT (0.46) MAPTTDP1L3MBTL1MEN1KMT2A
SCHEMBL3410083 0.80 LMNA (0.48) MAPTTDP1L3MBTL1MEN1KMT2A
SCHEMBL3409992 0.79 POLB (0.50) MAPTTDP1L3MBTL1MEN1KMT2A
SCHEMBL3411549 0.76 NPC1 (0.49) MAPTTDP1L3MBTL1MEN1KMT2A
SCHEMBL3408224 0.74 MAPT (0.50) MAPTTDP1L3MBTL1MEN1KMT2A
SCHEMBL3408312 0.74 TDP1 (0.49) MAPTTDP1L3MBTL1MEN1KMT2A
SCHEMBL3405825 0.70 MAPT (0.55) MAPTTDP1L3MBTL1MEN1KMT2A
SCHEMBL3407592 0.68 MAPT (0.50) MAPTTDP1L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2264035-A1 Glycine B antagonists Merz Pharma GmbH & Co. KGaA (DE) 2010-12-22 EP claimed
EP-2264035-A1 Glycine B antagonists Merz Pharma GmbH & Co. KGaA (DE) 2010-12-22 EP disclosed